Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026

Same author

CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance.

Cancer immunology research·2026

Same author

Siglec-15 binds mucin-domain glycoproteins with extended glycans and marks an osteoclast-like, matrix remodeling myeloid state in human tumors.

Glycobiology·2026

Same author

Chimeric autoantibody receptor T cells for targeted depletion of myeloperoxidase-specific anti-neutrophil cytoplasmic antibody-producing B cells.

Frontiers in immunology·2026

Same author

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Cancer·2026

Same author

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

Nature medicine·2026

Search research articles

相关实验视频

Updated: Mar 7, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

糖基工程CAR-T细胞以克服加勒-3介导的免疫抑制.

Lee Seng Lau¹, Maria Suarez¹, Brandon Fernandez¹

¹Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.

Frontiers in immunology

|March 6, 2026

概括

化学抗原受体 (CAR) -T细胞疗法显示出希望,但面临挑战. 在CAR-T细胞中增强ST6GAL1的表达,通过减少来自galectin-3的免疫抑制来改善它们的持久性和抗瘤活性.

关键词:

在CAR-T细胞中.癌症葡萄糖生物学癌症免疫疗法免疫疗法质素是一种质素.化修饰的修饰方法

更多相关视频

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

相关实验视频

Last Updated: Mar 7, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

科学领域:

免疫学免疫学免疫学
细胞疗法细胞疗法
葡萄糖生物学葡萄糖生物学

背景情况:

卡尔-T细胞疗法对B细胞恶性瘤有效,但由于持久性和毒性而受到限制.
T细胞功能受到甘氨酸特征和加勒素相互作用的影响.
卡尔-T细胞可能具有甘氨酸特征,使它们易受免疫抑制性加勒素的影响.

研究的目的:

研究加勒-3在CAR-T细胞功能中的作用.
为了确定CAR-T细胞是否表现出加列-3结合甘氨酸和减少ST6GAL1表达.
探索向化作为一种提高CAR-T细胞疗效的策略.

主要方法:

公共数据挖掘,糖化学物质,以及对加列结合和糖转移酶表达的评估.
对抗CD19的CAR-T细胞和与淋巴瘤相关的微环境的分析.
在CAR-T细胞中对ST6GAL1表达的遗传强制.

主要成果:

在淋巴瘤微环境中,加列-3的含量升高;CAR-T细胞显示加-3结合甘氨酸的增加和减少ST6GAL1.
在CAR-T细胞中强化ST6GAL1阻断了Gal-3结合,并逆转了Gal-3介导的免疫抑制.
增强ST6GAL1的CAR-T细胞保持了瘤杀伤活性,改善了抗瘤反应,并在体内持续性增加.

结论:

盖列-3是一种显著的外部抑制CAR-T细胞功能的抑制剂.
通过ST6GAL1进行向细胞表面α2,6化是一种可行的策略,可以改善CAR-T细胞的抗性.
这种方法在免疫抑制环境中增强了CAR-T细胞的持久性和抗瘤功效.